Shorter radiation combo may boost rectal cancer remission
NCT ID NCT07469306
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two treatments for locally advanced rectal cancer: a shorter course of radiation plus chemotherapy (CAPOX) and immunotherapy (tislelizumab) versus a longer course of chemoradiation plus the same immunotherapy. The goal is to see which approach leads to a higher rate of complete tumor disappearance. About 130 adults aged 18-75 with a specific type of rectal cancer will participate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Jinjiang Municipal Hospital
Quanzhou, Fujian, 362200, China
-
The Second Hospital of Longyan
Longyan, Fujian, 364000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could cutting one amino acid make rectal cancer treatment more effective?
- Can a targeted radiation combo boost rectal cancer remission?
- Can a short burst of radiation plus triple chemotherapy wipe out rectal cancer before surgery?
- MRI-Guided radiation boosts hopes for rectal cancer patients
- Timing of chemo may boost rectal cancer remission
- Immune-boosting combo aims to wipe out rectal cancer before surgery